secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001193125-23-288474
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace enters $3.7M collaboration with Rapport for Phase 2a trial of RAP compound
--------------------------------------------------------------------------------

- Agreement with Rapport Therapeutics to support Phase 2a trial of GAMA 8 Receptor-Associated Protein (RAP) compound.
- NeuroPace provides site data and monitoring capabilities for RNS System patients enrolled in the trial.
- Agreement spans nine quarters (Q4 2023 to Q4 2025) with milestones, subject to early termination provisions.
- Total anticipated revenue from collaboration is approximately $3.7 million, including a trial initiation payment in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000119312523288474/0001193125-23-288474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000119312523288474/d601207d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-288474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer